Influence of TACE combined with hepatectomy on clinical efficacy and safety of patients with BCLC-B stage hepatocellular carcinoma
[Objective]To investigate the influence of TACE combined with hepatectomy on clinical efficacy and safety of patients with BCLC-B stage hepatocellular carcinoma.[Methods]Ninety-two patients with BCLC stage B liver cancer admitted to the Department of General Surgery of the Fifth People's Hospital of Pingdingshan in Henan Province from January 2012 to May 2020 were treated with TACE combined with hepatectomy.The serum indexes of liver function and prothrombin time(PT)before and after operation were compared,and the overall survival time and progression free time were recorded.The effects of baseline liver function,preoperative TACE times,AFP decline after the last TACE and mRECIST evaluation results on progression free survival time were analyzed.[Results]The levels of AST,ALT,TBil and PT in 1 week after operation of all patients were significantly higher than base line and before treatment(P<0.05).The levels of Alb in 1 week and 1 month after treatment of all patients were significantly lower than base line(P<0.05).The PFS of patients with AFP decrease before operation were significantly longer than patients without AFP decrease(P<0.05).The PFS of patients with CR+PR before operation were significantly longer than patients with SD+PD(P<0.05).[Conclusion]TACE combined with hepatectomy in the treatment of patients with BCLC-B stage hepatocellular carcinoma possess the good clinical effects and safety,and the patients with decreased AFP after the last TACE and CR+PR before operation evaluated by mRECIST have longer median progression-free survival time.